Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: A phase i study

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 5, 2013, Pages 1000-1006

  Passoni, Paolo ^a   Reni, Michele ^a   Cattaneo, Giovanni M ^a   Slim, Najla ^a   Cereda, Stefano ^a   Balzano, Gianpaolo ^a   Castoldi, Renato ^a   Longobardi, Barbara ^a   Bettinardi, Valentino ^a   Gianolli, Luigi ^a   Gusmini, Simone ^a   Staudacher, Carlo ^a   Calandrino, Riccardo ^a   Di Muzio, Nadia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES; PATIENT MONITORING; PHYSICAL THERAPY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; TOXICITY;

DOSE LIMITING TOXICITY; FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY; INDUCTION CHEMOTHERAPY; INTERNAL TARGET VOLUME; METHODS AND MATERIALS; PANCREATIC ADENOCARCINOMA; PLANNING TARGET VOLUMES; SIMULTANEOUS INTEGRATED BOOSTS;

TUMORS;

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DUODENITIS; ESOPHAGUS VARICES; FEMALE; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HAND FOOT SYNDROME; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; NAUSEA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; STOMACH ULCER; TOMOTHERAPY; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD VESSEL; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECTS; DUODENUM; FEASIBILITY STUDY; IMAGE GUIDED RADIOTHERAPY; INTESTINE MUCOSA; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; ORGANS AT RISK; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; STOMACH MUCOSA; VASCULARIZATION;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD VESSELS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; DUODENUM; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GASTRIC MUCOSA; HUMANS; INDUCTION CHEMOTHERAPY; INTESTINAL MUCOSA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; ORGANS AT RISK; PANCREATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; TUMOR BURDEN;

EID: 84888233312     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.09.012     Document Type: Article

References (20)

1. F. Huguet, N. Girard, and C.S. Guerche Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review J Clin Oncol 27 2009 2269 2277
2. B. Chauffert, F. Mornex, and F. Bonnetain Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study Ann Oncol 19 2008 1592 1599
3. P.J. Loehrer Sr, Y. Feng, and H. Cardenes Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial J Clin Oncol 29 2011 4105 4112
4. K. Johung, M.W. Saif, and B.W. Chang Treatment of locally advanced pancreatic cancer: the role of radiation therapy Int J Radiat Oncol Biol Phys 82 2012 508 518
5. P. Hammel, F. Huguet, and J.-L. Van Laethem Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study Paper presented at: XIII Annual Meeting of ASCO. City, State J Clin Oncol 31,15 suppl May 20 2013 [Abstract LBA4003]
6. A.G. Morganti, M. Massaccesi, and G. La Torre A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer Ann Surg Oncol 17 2010 194 205
7. S. Gillen, T. Schuster, and C. Meyer Zum Büschenfelde Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
8. P. Mancosu, V. Bettinardi, and P. Passoni Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma Radiother Oncol 87 2008 339 342
9. G. Sangalli, P. Passoni, and G.M. Cattaneo Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies Acta Oncol 50 2011 72 80
10. G.M. Cattaneo, P. Passoni, and G. Sangalli Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: evaluation and reproducibility Radiother Oncol 97 2010 525 529
11. E. Ben-Josef, M. Schipper, and I.R. Francis A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 84 2012 1166 1171
12. F. Huguet, K.A. Goodman, and D. Azria Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations Int J Radiat Oncol Biol Phys 83 2012 1355 1364
13. M.P. Mac Manus, R.J. Hicks, and J.P. Matthews Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer J Clin Oncol 21 2003 1285 1292
14. R.J. Hicks Role of 18F-FDG PET in assessment of response in non-small cell lung cancer J Nucl Med 50 suppl 1 2009 31S 42S
15. B. Jones, and R.G. Dale Mathematical models of tumour and normal tissue response Acta Oncol 38 1999 883 893
16. M. Reni, S. Cereda, and A. Rognone A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) Cancer Chemother Pharmacol 69 2012 115 123
17. G.M. Cattaneo, P. Passoni, and B. Longobardi Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma Radiother Oncol 108 2013 66 71
18. M.H. Katz, J.B. Fleming, and P. Bhosale Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators Cancer 118 2012 5749 5756
19. F. Huguet, T. André, and P. Hammel Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 2007 326 331
20. M.M. Poppe, V. Narra, and N.J. Yue A comparison of helical intensity-modulated radiotherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer Med Dosim 36 2011 351 357